Target intelligence / Profile preview

Heparan-sulfate 6-O-sulfotransferase 2 (HS6ST2)

Target
HS6ST2
Molecular classification
Enzyme, Transferase
01

Overview

Heparan-sulfate 6-O-sulfotransferase 2 (HS6ST2) is an enzyme belonging to the heparan sulfate sulfotransferase family. It catalyzes the transfer of sulfate from 3′-phosphoadenosine 5′-phosphosulfate (PAPS) to the 6-O position of N-sulfoglucosamine residues in heparan sulfate (HS) proteoglycans, thereby modifying the structure and biological activity of HS chains[1][5][6]. HS6ST2 plays a crucial role in cell signaling by regulating interactions between heparan sulfate proteoglycans and multiple ligands (such as growth factors), impacting processes like cell growth, differentiation, adhesion, and migration[3]. It is expressed in a tissue-specific manner, with isoforms present in the brain, eye, ovary, placenta, and fetal kidney, and is implicated in embryonic development and disease pathways. Alterations in HS6ST2 expression or function are associated with neurodevelopmental disorders, cancer progression, and fibrotic diseases. Its expression correlates with prognosis, immune cell infiltration, and drug resistance in multiple cancer types[2]. No direct drugs targeting HS6ST2 are currently listed, nor specific mechanisms of action for such drugs.

Other names
PSEC0092HS6ST-2MRXSPMheparan-sulfate 6-O-sulfotransferase 2HS6ST2
02

Biological functions

Heparan sulfate (HS) modificationTransfer of sulfate to the 6-O position of N-sulfoglucosamine in heparan sulfate proteoglycansRegulation of cell growthCell differentiationCell adhesionCell migration
03

Disease associations

CancerNeurodevelopmental disorders (e.g., intellectual disability, optic disc/stalk morphogenesis)Cartilage cancerIdiopathic pulmonary fibrosisMyopia
04

Safety considerations

No direct safety concerns reported, but alteration in HS6ST2 function associated with developmental impairment and tumorigenesis
05

Biomarkers

Prognostic marker in several malignancies (e.g., renal cell carcinoma, papillary thyroid cancer, lung adenocarcinoma, etc.)Differential methylation patterns in idiopathic pulmonary fibrosis and susceptibility to COVID-19

Beyond the preview

Go deeper on Heparan-sulfate 6-O-sulfotransferase 2 (HS6ST2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heparan-sulfate 6-O-sulfotransferase 2 (HS6ST2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call